Clinical Cancer Research · 2022 · 16 citations · 45 references
MedicineOncologyPharmacologyCancer PharmacologyMetastasisOncology PharmacotherapyBone MetastasisBone TumorsCancer ImmunotherapyImmunotherapy For Solid TumorsTargeted TherapyToxicity ManagementDose Escalation EvaluationDose Escalation TherapyEfficacy Data EvaluationImmunotherapy For Bone SarcomasMaintenance Therapy TrialsOsteosarcoma TreatmentPd-l1 BlockadeSafety Profile Characterization
PURPOSE: We investigated the safety and preliminary efficacy of anti-PD-L1 antibody (ZKAB001) as maintenance therapy for localized patients with high-grade osteosarcoma to reduce the risk of recurrence and metastasis. PATIENTS AND METHODS: This open-label Phase I/II study was divided into dose-escalation Phase I and expansion Phase II. Phase I used a 3+3 design with ZKAB001 at three escalating doses ranging: 5, 10, 15 mg/kg every 2 weeks in 9 patients with localized high-grade osteosarcoma and Phase II tested 10 mg/kg in 12 patients for up to 24 cycles. Primary endpoints were safety and tolerability assessed using CTCAE4.0.3. RESULTS: Between October 2018 and 2019, 21 eligible patients were enrolled and accepted ZKAB001 treatment: 9 in the dose-escalation phase, and 12 in expansion phase. Six patients with disease progression withdrew from this study and follow-up is ongoing. The MTD was not defined in Phase I. All doses had a manageable safety profile. The recommended dose in Phase II was set at 10 mg/kg. Most frequent immune-related adverse events were thyroiditis (76.2%) and dermatitis (42.9%). Only 1 (4.8%) of 21 patients had a Grade 3 skin rash. The median 3-year event-free survival (EFS) and overall survival (OS) were not established; however, 24-month EFS was 71.4% (95% confidence interval, 47.2-86.0) and 2-year OS was 100%. Preliminary efficacy data showed EFS benefits in patients with PD-L1 positive or an MSI-H sub-population. CONCLUSIONS: Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized patients with osteosarcoma.
45
Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 3K citations · Full text
Life Sciences, Immunology, Oncology +17
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita, Martin Lauss, Adriana Sanna et al. · Nature · 2020 · 2.3K citations · Full text
Medicine, Immunology, Oncology +12
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Stefan Bielack, Beate Kempf‐Bielack, G. Delling et al. · Journal of Clinical Oncology · 2002 · 1.8K citations
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Se Hoon Park, Éric Voog et al. · New England Journal of Medicine · 2020 · 1.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12